Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Visit

ESMO Breast 2024

15–17 May 2024 | Berlin, Germany

The European Society for Medical Oncology (ESMO) Breast Cancer Conference will be held in Berlin, Germany on the 15-17 May. This annual meeting will deliver the latest updates in breast cancer, presented by leading, world-renowned experts. In the meantime, watch our exclusive breast cancer content covering a wide variety of topics and perspectives!

KEYNOTE-355: outcomes in pts discontinuing chemo before pembro and in pts with immune-mediated AEs

Hope Rugo • 12 May 2023

MONALEESA-2: ribociclib + letrozole in pts with de novo metastatic disease and late recurrence

Patrick Neven • 11 May 2023

HER2DX and pCR in HER2-positive breast cancer: a combined analysis of 4 neoadjuvant studies

Adrienne Waks • 12 May 2023

Investigating targeted therapy combinations in metastatic HR+ breast cancer

Komal Jhaveri • 11 May 2023

PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations

Timothy Yap • 7 Apr 2024

ADAPT trial: Endocrine + ribociclib vs. chemotherapy in HR+/HER2- early breast cancer

Rick Baehner • 6 Dec 2023

NATALEE: ribociclib + NSAI as adjuvant treatment in patients with HR+/HER2− early breast cancer

Gabriel N. Hortobagyi • 6 Dec 2023

PARSIFAL-LONG: fulvestrant and palbociclib vs letrozole and palbociclib

Antonio Llombart-Cussac • 7 Dec 2023

Use of checkpoint inhibitors in breast cancer treatment

Michail Ignatiadis • 14 Mar 2024

Immune-related AEs in patients with breast cancer treated with IO

Neelima Vidula • 6 Dec 2023

Trastuzumab deruxtecan in patients with breast cancer with brain metastases

Janice Wing-Hang Tsang • 21 Oct 2023

Real-word efficacy of sacituzumab govitecan in metastatic triple-negative breast cancer

Kevin Kalinsky • 22 Oct 2023